Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings

WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.

Continue reading

NuvOx Announces First Patient in Phase IIb Stroke Trial

Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO).

The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between the National Institute for Health Care Research (NIHR) and the Medical Research Council (MRC). The trial is also co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.Continue reading

AZBio Celebrates Trailblazers 2025

AZBio and members of the Arizona Business and Bioscience Community came together honor Arizona Legislators and State and Local Elected Officials who have made it possible for the Arizona Bioscience Industry to gain national recognition, build capital infrastructure, and take its place as a leader in both scientific discovery and job growth.Continue reading